Welcome to our dedicated page for LKYSD news (Ticker: LKYSD), a resource for investors and traders seeking the latest updates and insights on LKYSD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LKYSD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LKYSD's position in the market.
Numinus Wellness reported strong Q3 2021 results with a cash balance of $63.2 million as of May 31, 2021. The company generated revenues of $562,076 for the quarter, reflecting a 160% year-over-year increase. Key developments included the expansion of its clinic network and the announcement of a Phase 1 clinical trial for a Psilocybe extract. The acquisition of the Neurology Center of Toronto for $1.1 million positions Numinus for growth in psychedelic neurology. Overall, Numinus is poised for rapid growth and innovation in mental health therapies.
Numinus Wellness announced Health Canada's approval for a MAPS-sponsored study on MDMA-assisted therapy for PTSD. This single-arm, open-label study aims to assess safety and feasibility, paving the way for a regulated model of therapy in Canada. Numinus focuses on expanding access to these therapies, targeting patients with limited treatment options. The study will gather data on the efficacy of MDMA therapy while adhering to COVID-19 protocols. This initiative builds on positive results from MAPS' Phase 3 trial, where 88% of participants showed significant symptom reduction.
Numinus Wellness Inc. (TSXV: NUMI), a mental health care company, has announced the grant of 1,825,000 stock options to its directors, officers, and employees, pending regulatory approval. Out of these, 810,000 options for directors and one officer have an exercise price of $0.90, expiring on May 19, 2023. The remaining 1,015,000 options for employees have prices ranging from $0.87 to $1.00, with expiry dates between May 1 and May 17, 2023. This grant constitutes 4.42% of the company's total issued shares, with a limit of 10% set by the Stock Option Plan.
Numinus Wellness Inc. has officially graduated to Tier 1 Issuer status on the TSX Venture Exchange as of June 18, 2021. This advancement indicates the company's robust growth and scalability in the mental health sector, particularly in psychedelic-assisted therapies. The upgrade allows Numinus to benefit from enhanced service standards and greater access to institutional investors. CEO Payton Nyquvest highlighted plans for clinic acquisitions and clinical trials aimed at increasing shareholder value and expanding their innovative healthcare solutions.
Numinus Wellness has established a General Advisory Council that includes leaders in technology, pharmacology, and mental health, aimed at enhancing their mission of providing safe, evidence-based psychedelic-assisted psychotherapy. The council, featuring prominent figures like Jamie Wheal and Ben Nemtin, seeks to leverage diverse expertise to support innovative mental healthcare solutions. CEO Payton Nyquvest emphasized the importance of varied perspectives in advancing mental health treatment. These experts aim to address the growing need for mental health support, particularly in light of challenges posed by the COVID-19 pandemic.
